- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06736197
An Algorithmic Approach to Preoxygenation
An Algorithmic Approach to Preoxygenation: Stepwise Addition of Pressure Support and Positive End-expiratory Pressure When Tidal Volume Breathing is Inadequate. A Randomised Controlled Trial
The aim of this randomized controlled trial is to evaluate an algorithmic approach to gradually adding pressure-supported ventilation and end-tidal positive pressure when conventional tidal volume breathing is insufficient for adequate preoxygenation. The main question it aims to answer is:
- Will the proportion of patients receiving preoxygenation increase?
- Will the duration of preoxygenation decrease?
Participants will;
- 200 patients who were planned to undergo general anesthesia for elective surgeries
- aged between 18 and 65 years
- ASA 1-2 physical status
- ETO2 <90% at the end of the 3rd minute with spontaneous tidal volume breathing
Study Overview
Status
Intervention / Treatment
Detailed Description
The patients were randomly assigned to one of two groups (Group TVB and Group PSV) according to a computer-generated randomisation table. In the patients included in Group TVB, the tidal volume breathing was maintained for a further two minutes. Group PSV received inspiratory pressure support of 6 cm H2O for +1 min. At the end of four minutes, patients whose ETO₂ value had not reached a minimum of 90% were randomly divided once more into two groups. One group continued with PSV, while the other was administered 4 cm H₂O PEEP in addition to PSV (Group PSV+PEEP).
When adequate preoxygenation was achieved, the duration of preoxygenation, SpO2, end-tidal carbon dioxide (ETCO2), arterial blood pressures and heart rate values were recorded. Any adverse effects such as discomfort or gastric distension were noted.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Denizli, Turkey
- Pamukkale University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Elective surgeries general anaesthesia was planned for a patient aged 18-65 years with ASA 1-2 physical condition.
Exclusion Criteria:
- Haemodynamically unstable, preoperative oxygen support such as increased intracranial or intraocular pressure, to be operated on by thoracic surgery have conditions in which positive pressure ventilation may be indirectly harmful, BMI≥35 kg/m2, pregnant, undergoing emergency surgery and causing leakage in mask ventilation bearded male patients were not included in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group TVB
Group TVB patients who could not reach 90% ETO2 at the end of the 3rd minute were continued with tidal volume breathing.
|
Patients who could not reach ETO2 value 90 with tidal volume breathing for 3 min were included in Group TVB tidal volume breathing was continued for 2 min.
Other Names:
|
|
Experimental: Group PSV
Group PSV received 6 cm H2O positive pressure ventilation.
|
Preoxygenation was continued by providing 6cmH2O pressure support to the patients included in this group.
|
|
Experimental: Group PSV+PEEP
In addition to 6 cmH2O pressure support, 4 cmH2O end-expiratory positive pressure support was added to the patients included in Group PEEP.
|
Preoxygenation was continued by providing 6cmH2O pressure support to the patients included in this group.
At the 4th minute, preoxygenation was continued by adding 4 cmH2O positive end-expiratory pressure to the same 6 cmH2O pressure support for 1 min in patients whose end-tidal O2 value still reached 90% and who were included in this group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adequate preoxygenation.
Time Frame: The moment when the end-tidal oxygen value of patients with insufficient preoxygenation at the end of the third minute with spontaneous tidal volume breathing is 90 and above.
|
The moment of ensuring adequate preoxygenation when the end-tidal oxygen value is 90 and above.
|
The moment when the end-tidal oxygen value of patients with insufficient preoxygenation at the end of the third minute with spontaneous tidal volume breathing is 90 and above.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse effects
Time Frame: Within 5 min until target preoxygenation is reached.
|
Any adverse effects such as discomfort or gastric distension were noted.
|
Within 5 min until target preoxygenation is reached.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PamukkaleUCTanriverdi-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Preoxygenation
-
Institute of Mountain Emergency MedicineRecruiting
-
Prince Sultan Military Medical CityActive, not recruitingPreoxygenationSaudi Arabia
-
University of British ColumbiaCompleted
-
Baskent UniversityCompleted
-
University of British ColumbiaCompleted
-
Johannes Gutenberg University MainzCompleted
-
Kahramanmaras Sutcu Imam UniversityCompletedPreoxygenationTurkey
-
Maisonneuve-Rosemont HospitalCompleted
-
Peking University People's HospitalUnknown
-
University of ParmaUnknown
Clinical Trials on Group TVB
-
Sagimet Biosciences Inc.CompletedMASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)China, United States
-
David E GerberCancer Prevention Research Institute of Texas; Gateway for Cancer Research; Sagimet...Active, not recruiting
-
Ascletis Pharmaceuticals Co., Ltd.Completed
-
Sagimet Biosciences Inc.CompletedSolid Malignant TumorUnited Kingdom, United States
-
Sagimet Biosciences Inc.RecruitingAcneAustralia, United States
-
Sagimet Biosciences Inc.Active, not recruitingHealthy VolunteersUnited States
-
Weill Medical College of Cornell UniversitySagimet Biosciences Inc.RecruitingProstatic Neoplasms, Castration-ResistantUnited States
-
Sagimet Biosciences Inc.CompletedCirrhosis | Hepatic Impairment | Non-alcoholic SteatohepatitisUnited States, Hungary
-
Sagimet Biosciences Inc.CompletedMetabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver DiseaseUnited States, Canada, Puerto Rico, Poland
-
Sagimet Biosciences Inc.WithdrawnNonalcoholic Steatohepatitis | Nonalcoholic Fatty Liver | NASH | MASLD | MASH | Metabolic Dysfunction-Associated Steatohepatitis | Metabolic Dysfunction-Associated Steatotic Liver Disease